GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET FORECAST 2024-2032
世界の抗体薬物複合体（ADC）製造市場予測 2024-2032年
The global antibody drug conjugates contract manufacturing market is estimated to progress at a CAGR of 12.47% during the forecast period 2024-2032.
世界の抗体薬物複合体（ADC）製造市場は、2024年から2032年の予測期間中に12.47%のCAGRで成長すると推定されています。
Numerous aspects stimulate the market growth: the rising demand for targeted therapies, the growing inclination towards contract manufacturing companies as an economical choice, the surging global cancer incidence, and advancements in drug conjugation technologies.
REPORT SYNOPSIS
| REPORT SCOPE | DETAILS |
|---|---|
| Market Forecast Years | 2024-2032 |
| Base Year | 2023 |
| Market Historical Years | 2018-2022 |
| Forecast Units | Revenue ($ Million) |
| Segments Analyzed | Phase, Linker, and Condition |
| Geographies Analyzed | North America, Europe, Asia-Pacific, and Rest of World |
| Companies Analyzed | Sterling Pharma Solutions, Recipharm AB, Lonza Group, Piramal Pharma Solutions, AbbVie Inc (AbbVie Contract Manufacturing), Merck KGaA, Catalent Inc, Sartorius AG, WuXi Biologics, Samsung Biologics Co Ltd, Cambrex Corporation, Cerbios-Pharma SA |